Richly priced here in the mid teens. Don't expect any buyout until and "IF" the FDA approves. A partner
is possible, but one would of thought there would be one by now, so again not likely ahead of FDA. Europe is moving along, but needs to ramp up more quickly. Not the insiders fault, it's just a longer process than many anticipated.
Still working on my DD and curious if InterMune receives any royalties from Japan, where drug has been approved. Did read anything on it in last report transcript. With the 9-3 & 7-5 favorable panel votes in 2010, followed by non FDA approval, I'm just glad I came along after the carnage.
I made a killing in DNDN over 13 months, buying 7.30 per share and selling day of FDA approval. I believe InterMune will receive FDA approval on it's second PHASE III in 2014. Hoping for shares to pullback to 9-10 range, but if this decides to continue back higher, I'll start scaling in my long position.
Shionogi in Japan licenses Pirfenidone separately from the same party that Intermune does in the rest of the world. Intermune pays Shionogi a small fee to cover possible use of Shionogi data in setting price levels in European countries.